Atlas Trials

Unresectable Gastroesophageal Junction Adenocarcinoma

15 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Unresectable Gastroesophageal Junction Adenocarcinoma

RecordFirmDate
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma (NCT05041153)M.D. Anderson Cancer Center2022-02-14
Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery (NCT04391049)NRG Oncology2021-12-02
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661)National Cancer Institute (NCI)2021-08-09
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers (NCT04460937)National Cancer Institute (NCI)2021-04-09
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer (NCT03641313)National Cancer Institute (NCI)2020-11-16
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer (NCT04522336)M.D. Anderson Cancer Center2020-09-16
MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (NCT03739801)University of Southern California2020-04-06
Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma (NCT03395847)M.D. Anderson Cancer Center2018-02-09
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery (NCT03008278)National Cancer Institute (NCI)2018-02-06

Track Unresectable Gastroesophageal Junction Adenocarcinoma automatically

Every clearance here is in the API, with alerts when new ones post.